"Hodgkin Lymphoma Research Updates From Dr. Joshua Brody"
What’s new for those living with Hodgkin lymphoma? Although today’s standard of care cures some, the ever-evolving field of cancer research is finding innovative approaches to benefit a greater number of patients. Joshua Brody, MD, assistant professor of medicine, hematology and medical oncology, director of the Lymphoma Immunotherapy Program at the Icahn School of Medicine at Mount Sinai, discusses recent advances in immunotherapy, anti-body drug conjugates, and targeted and combination therapies for Hodgkin lymphoma patients. Dr. Brody also shares results from the ECHELON-1 trial, the rate of progression-free survival, and how the side effect profile compares to standard therapies.
- Joshua Brody, MD, Assistant Professor, Medicine, Hematology and Medical Oncology, Director, Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai